EP0667870A4 - Zusammensetzungen und verfahren zur modifizierung der regulatorischen aktivität von tgf-beta. - Google Patents

Zusammensetzungen und verfahren zur modifizierung der regulatorischen aktivität von tgf-beta.

Info

Publication number
EP0667870A4
EP0667870A4 EP94900408A EP94900408A EP0667870A4 EP 0667870 A4 EP0667870 A4 EP 0667870A4 EP 94900408 A EP94900408 A EP 94900408A EP 94900408 A EP94900408 A EP 94900408A EP 0667870 A4 EP0667870 A4 EP 0667870A4
Authority
EP
European Patent Office
Prior art keywords
tgf
modifying
compositions
methods
regulatory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94900408A
Other languages
English (en)
French (fr)
Other versions
EP0667870A1 (de
Inventor
Michelle Letarte
Joan Massague
Carmelo Bernabeu
Sela Cheifetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Consejo Superior de Investigaciones Cientificas CSIC
Memorial Sloan Kettering Cancer Center
Original Assignee
HSC Research and Development LP
Consejo Superior de Investigaciones Cientificas CSIC
Sloan Kettering Institute for Cancer Research
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/968,953 external-priority patent/US5830847A/en
Application filed by HSC Research and Development LP, Consejo Superior de Investigaciones Cientificas CSIC, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center filed Critical HSC Research and Development LP
Publication of EP0667870A1 publication Critical patent/EP0667870A1/de
Publication of EP0667870A4 publication Critical patent/EP0667870A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP94900408A 1992-10-30 1993-10-26 Zusammensetzungen und verfahren zur modifizierung der regulatorischen aktivität von tgf-beta. Withdrawn EP0667870A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96895492A 1992-10-30 1992-10-30
US968954 1992-10-30
US968953 1992-10-30
US07/968,953 US5830847A (en) 1992-10-30 1992-10-30 Soluble TGF-β-binding endoglin polypeptides and homodimers
PCT/US1993/010307 WO1994010187A1 (en) 1992-10-30 1993-10-26 COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)

Publications (2)

Publication Number Publication Date
EP0667870A1 EP0667870A1 (de) 1995-08-23
EP0667870A4 true EP0667870A4 (de) 1998-04-01

Family

ID=27130519

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94900408A Withdrawn EP0667870A4 (de) 1992-10-30 1993-10-26 Zusammensetzungen und verfahren zur modifizierung der regulatorischen aktivität von tgf-beta.

Country Status (5)

Country Link
EP (1) EP0667870A4 (de)
JP (1) JPH08504577A (de)
AU (1) AU5541094A (de)
CA (1) CA2147754A1 (de)
WO (1) WO1994010187A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
CA2156767A1 (en) * 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
WO2002067978A1 (en) * 2001-02-23 2002-09-06 Wyeth Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
PL2083863T3 (pl) 2006-10-03 2015-08-31 Genzyme Corp Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
RU2559532C2 (ru) 2006-11-02 2015-08-10 Акселерон Фарма, Инк. Антагонисты рецептора и лигандов alk1 и их применение
EP3398966A1 (de) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Verfahren und zusammensetzungen zur modulation von angiogenese und pericytzusammensetzung
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
CA2833747C (en) * 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
US20150202260A1 (en) 2013-10-25 2015-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
EP3804760A1 (de) 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Therapeutikum für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9410187A1 *

Also Published As

Publication number Publication date
WO1994010187A1 (en) 1994-05-11
CA2147754A1 (en) 1994-05-11
JPH08504577A (ja) 1996-05-21
EP0667870A1 (de) 1995-08-23
AU5541094A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
ZA939656B (en) Microvicidal compositions.
EP0667870A4 (de) Zusammensetzungen und verfahren zur modifizierung der regulatorischen aktivität von tgf-beta.
EP0650370A4 (de) Auf spezifische gewebe abzielende verfahren und zusammensetzungen.
TW351991U (en) Diaper
EP0597463A3 (en) Thermotherapiesonde.
EP0598412A3 (de) Hautschutzmittel zum Schutz der menschlichen Haut.
EP0580285A3 (de) Selbsttätige Wiedereinschalter.
EP0611302A4 (de) Verfahren und zusammensetzungen zur behandlung von allergischen reaktionen.
EP0652749A4 (de) Verfahren und Zusammensetzungen zur Hemmung der 5 Alpha - Reduktase Aktivität.
EP0671929A4 (de) Zusammensetzungen.
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
ZA919900B (en) Phosphate esters and compositions containing them.
EP0567088A3 (de) Verfahren zur Herstellung eines Amylase-Inhibitors.
EP0572808A3 (de) Antiblockierregelsystem.
EP0656791A4 (de) Therapeutische zusammensetzungen und verfahren unter verwendung von pqq.
AU5602494A (en) Catalytic aromatic saturation in the presence of halide
HU9303342D0 (en) 2-alkoxy-2-imidazoline-5-one derivatives and fungicidal compositions containing them
GB9201761D0 (en) Active cancellation
GR3026571T3 (en) Preparation of 2-H-heptafluoropropane.
ZA93886B (en) Bleaching regulator compositions and bleaching processes using them.
GR3024654T3 (en) Benzofuranone and benzodifurantrione derivatives and process for the preparation of benzodifuranones.
GB9225701D0 (en) Gantry
AU3737289A (en) Agent for treating pancreatitis or the like
EP0592354A3 (de) Vakuum-Zentrifuge.
GB9222985D0 (en) Use of the tarchonanthus camphoratus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

RHK1 Main classification (correction)

Ipc: C07H 21/02

RHK1 Main classification (correction)

Ipc: C12N 15/12

A4 Supplementary search report drawn up and despatched

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990503